Dr. Cindy Lynn Lamerson, MD

Dr. Lamerson practices at Nevada Center For Dermatology in Reno, Nevada.

Dr. Lamerson's NPI, 1699763201, was assigned on October 7, 2005. Dr. Lamerson graduated from VCU School of Medicine in 1993. Dr. Lamerson holds Nevada license 8902.

Dr. Lamerson's primary practice is Nevada Center for Dermatology, at 650 Sierra Rose Dr Suite A Suite A, Reno, NV 89511-2081. The practice phone is (775) 827-8100.

Dr. Lamerson's primary practice is Nevada Center For Dermatology in Reno, Nevada. Dr. Lamerson is also affiliated with Renown Regional Medical Center. The medical group on file is Nevada Center for Dermatology.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lamerson practices, 2 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Lamerson's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Lamerson is board certified in dermatology by the American Board of Dermatology. Dmand AI has Dr. Lamerson's licenses on file in 3 states: Nevada, Ohio and Kentucky.

Dmand AI lists acne, acute skin infection, benign or precancerous skin growths, cancerous skin growth removal, contact dermatitis, facial skin infection, hives and itchy rashes among the conditions Dr. Lamerson treats.

CMS data shows 6,184 Medicare services from Dr. Lamerson across 35 procedure codes in 2024, for 1,256 Medicare patients. Medicare paid $508,022 for them. Every service was in an office.

CMS counts 1,256 Medicare patients who saw Dr. Lamerson in 2024. The largest group is 65 to 74, with 603 patients. 75% of them have high cholesterol, and 57% have high blood pressure. Their average risk score is 0.93, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Lamerson's median patient age at 72, with 58% women.

In 2024, Dr. Lamerson wrote 801 Medicare Part D claims for 279 patients. 91% of them were for generic drugs. CMS names the drug for 651 of them, across 17 drugs with 11 or more claims each, at $152,679 in total drug cost. In 2023, CMS named 565 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 70 out of 100 for Dr. Lamerson for performance year 2024, reported as part of a group. Dr. Lamerson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 226 procedures of melanoma (skin cancer) excision by Dr. Lamerson, more than 98% of the clinicians it reports for that procedure.

Removal or shaving of skin growth: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 6 papers to Dr. Lamerson, published from 2012 to 2024. The most frequent topics are Obsessive-Compulsive Disorder. Dr. Lamerson's most frequent co-authors are Lesley M. Arnold, MD and Amanda Catherine Mullins, MD.

CMS Open Payments shows 602 general payments to Dr. Lamerson from 41 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 95% of the total. Abbvie Inc. paid the most, $1,666.

Dr. Lamerson graduated from VCU School of Medicine in 1993.

Dr. Lamerson is in network with 10 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.